Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and Target Occupancy of BIIB113 in Healthy Participants
NCT05195008Phase 1Completed
- Sponsor
- Biogen
- Start
- Jan 2022
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of BIIB113 in Alzheimer's disease (AD) (13 arms), sponsored by Biogen. Primary endpoints: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 85 days, Number of Participants With Clinically Significant Change From Baseline in Clinical Laboratory Parameters, Vital Signs, and 12-Lead Electrocardiogram (ECG) up to 85 days and 2 more. Started Jan 2022; status: completed.
02
Drugs
BIIB113
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05195008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05195008.